<?xml version="1.0" encoding="UTF-8"?>
<p id="para170">Post-hoc exploratory analyses were to define differences in progression-free survival between patients with CNS localisation at initial diagnosis and patients with CNS involvement at relapse, difference in progression-free survival between patients with histologically confirmed CNS disease and patients assessed with neuroimaging alone, the role of debulking R-CHOP and intrathecal chemotherapy, and the prognostic value of age, sex, performance status, lactate dehydrogenase serum concentration, sites of disease, response to the first two MATRix courses, a history of indolent lymphoma, and cell of origin.</p>
